BioNTech, Neon teams report personalized cancer vaccine data

In papers published in Nature, two groups each reported results from Phase I studies showing responses to personalized neoantigen cancer vaccines to treat melanoma. The groups included a team from BioNTech AG (Mainz, Germany), and a group including co-founders of Neon Therapeutics Inc. (Cambridge, Mass.).

In the BioNTech team's paper,